1,2-dimyristoylphosphatidylethanolamine (DMPE)

Also Known As:

DMPE; 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine; 1,2-ditetradecanoyl-sn-glycero-3-phosphoethanolamine; dimyristoyl cephalin; tetradecanoic acid, (1R)-1-((((2-aminoethoxy)hydroxyphosphinyl)oxy)methyl)-1,2-ethanediyl ester; Tetradecanoic acid, 1-((((2-aminoethoxy)hydroxyphosphinyl)oxy)methyl)-1,2-ethanediyl ester

Networked: 10 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Lipids: 114793
- Membrane Lipids: 1591
  - Phospholipids: 11903
    - Glycerophosphates: 118
      - Phosphatidic Acids: 358
        Glycerophospholipids: 689
        Phosphatidylethanolamines: 167
        1,2-dimyristoylphosphatidylethanolamine: 10

Experts

1.	Arpicco, Silvia: 2 articles (04/2020 - 01/2020)
2.	Giordani, Silvia: 2 articles (04/2020 - 01/2020)
3.	Suwalsky, M: 2 articles (11/2015 - 05/2009)
4.	Villena, F: 2 articles (11/2015 - 05/2009)
5.	Choi, Jun Ho: 1 article (12/2021)
6.	Hwang, Jae Ha: 1 article (12/2021)
7.	Kim, Kwang Seog: 1 article (12/2021)
8.	Lee, Sam Yong: 1 article (12/2021)
9.	Oh, Seong Jin: 1 article (12/2021)
10.	Boarino, Alice: 1 article (04/2020)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2020 - "All these promising attributes make CNT/HA200-DMPE a "smart" platform for tumor-targeted delivery of anticancer agents." 04/01/2020 - "In this study, we report the use of a hyaluronic acid-phospholipid (HA-DMPE) conjugate to target CD44 overexpressing cancer cells, while enhancing solubility of the nanoconstruct. " 01/01/1986 - "These differences are illustrated in the preparation and use of 186Re (Sn)-HEDP and 99mTc(Sn)-HEDP diphosphonate radiopharmaceuticals designed, respectively, for palliative therapy and diagnosis of metastatic cancer to bone, and in the preparation and biodistribution of tr[186Re(DMPE)2Cl2]+ and [186Re(DMPE)3]+, analogs to the potential myocardial perfusion imaging agents tr-[99mTc(DMPE)2Cl2]+ and [99mTc(DMPE)3]+. " 08/30/2022 - "In this study, we attached a hyaluronic acid-phospholipid (HA-DMPE) conjugate polymer to the BN-CNO's surface to improve its hydrophilicity and provide targetability toward HA-receptor overexpressing cancer cells. "
2.	Hemolysis 01/01/2016 - "crispum neutralized the oxidative capacity of HClO on DMPE bilayers; defocusing microscopy and hemolysis assays demonstrated the protective effect of S. " 11/01/2015 - "Results of its antioxidant properties showed that UA neutralized the oxidative capacity of HClO on DMPC and DMPE bilayers; SEM, DM and hemolysis assays demonstrated the protective effect of UA against the deleterious oxidant effects of HClO upon human erythrocytes. "
3.	Myocardial Ischemia (Ischemic Heart Diseases) 12/01/1982 - "The similar kinetics of Tc-99m DMPE compared to Tl-201 suggests its usefulness in the evaluation of ischemic heart disease."
4.	Neuroblastoma 05/01/2009 - "The capacity of zinc ions to perturb the bilayer structures of DMPC and DMPE was assessed by X-ray diffraction, DMPC large unilamellar vesicles (LUV) and IUM were studied by fluorescence spectroscopy, intact human erythrocytes were observed with scanning electron microscopy (SEM), and neuroblastoma cell morphology was observed under inverted microscope. "
5.	Ischemia 12/01/1982 - "The magnitude of Tc-99m DMPE uptake during reactive hyperemia was slightly less than that of Tl-201, but the decreased uptake with ischemia was about equal for the two agents. " 12/01/1982 - "After intravenous administration of Tc-99m DMPE the flow-dependent kinetics were studied in dogs during induced ischemia and during induced maximal reactive hyperemia. "

Related Drugs and Biologics

1.	Phospholipids (Phosphatides)
2.	Hyaluronic Acid (Hyaluronan)
3.	Polymers
4.	Dimyristoylphosphatidylcholine (DMPC)
5.	Unilamellar Liposomes
6.	Radiopharmaceuticals
7.	Oxidants (Oxidizing Agents)
8.	Zinc
9.	Etidronic Acid (HEDP)
10.	Ions

Related Therapies and Procedures

1.	Intravenous Administration
2.	Palliative Care (Palliative Therapy)